Updates on breast cancer genetics: Clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer

Hall, 1990, Linkage of early-onset familial breast cancer to chromosome 17q21, Science, 250, 1684, 10.1126/science.2270482 Narod, 1989, Early detection of hereditary medullary thyroid cancer with polymorphic DNA probes. Groupe d׳Etude des Tumeurs a Calcitonine, Henry Ford Hosp Med J, 37, 106 Miki, 1994, A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, 266, 66, 10.1126/science.7545954 Futreal, 1994, BRCA1 mutations in primary breast and ovarian carcinomas, Science, 266, 120, 10.1126/science.7939630 Tavtigian, 1996, The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds, Nat Genet, 12, 333, 10.1038/ng0396-333 Venkitaraman, 2014, Cancer suppression by the chromosome custodians, BRCA1 and BRCA2, Science, 343, 1470, 10.1126/science.1252230 Lord, 2012, The DNA damage response and cancer therapy, Nature, 481, 287, 10.1038/nature10760 Merajver, 1995, Somatic mutations in the BRCA1 gene in sporadic ovarian tumours, Nat Genet, 9, 439, 10.1038/ng0495-439 Hoskins, 1995, Assessment and counseling for women with a family history of breast cancer. A guide for clinicians, JAMA, 273, 577, 10.1001/jama.1995.03520310075033 Olopade, 2008, Advances in breast cancer: pathways to personalized medicine, Clin Cancer Res, 14, 7988, 10.1158/1078-0432.CCR-08-1211 Couch, 2015, Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer, J Clin Oncol, 33, 304, 10.1200/JCO.2014.57.1414 Antoniou, 2003, Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies, Am J Hum Genet, 72, 1117, 10.1086/375033 Ford, 1998, Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium, Am J Hum Genet, 62, 676, 10.1086/301749 van der Kolk, 2010, Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age, Breast Cancer Res Treat, 124, 643, 10.1007/s10549-010-0805-3 Meijers-Heijboer, 2000, Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation, Lancet, 355, 2015, 10.1016/S0140-6736(00)02347-3 Roa, 1996, Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2, Nat Genet, 14, 185, 10.1038/ng1096-185 Ferla, 2007, Founder mutations in BRCA1 and BRCA2 genes, Ann Oncol, 18, vi93, 10.1093/annonc/mdm234 Szabo, 1997, Population genetics of BRCA1 and BRCA2, Am J Hum Genet, 60, 1013 Begg, 2008, Variation of breast cancer risk among BRCA1/2 carriers, JAMA, 299, 194, 10.1001/jama.2007.55-a Wang, 2012, Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review, Mol Biol Rep, 39, 2109, 10.1007/s11033-011-0958-0 Judkins, 2012, Clinical significance of large rearrangements in BRCA1 and BRCA2, Cancer, 118, 5210, 10.1002/cncr.27556 Tai, 2007, Breast cancer risk among male BRCA1 and BRCA2 mutation carriers, J Natl Cancer Inst, 99, 1811, 10.1093/jnci/djm203 Evans, 2010, Risk of breast cancer in male BRCA2 carriers, J Med Genet, 47, 710, 10.1136/jmg.2009.075176 Malkin, 2011, Li-Fraumeni syndrome, Genes Cancer, 2, 475, 10.1177/1947601911413466 Hisada, 1998, Multiple primary cancers in families with Li-Fraumeni syndrome, J Natl Cancer Inst, 90, 606, 10.1093/jnci/90.8.606 Lammens, 2010, Regular surveillance for Li-Fraumeni Syndrome: advice, adherence and perceived benefits, Fam Cancer, 9, 647, 10.1007/s10689-010-9368-z Masciari, 2012, Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort, Breast Cancer Res Treat, 133, 1125, 10.1007/s10549-012-1993-9 Olivier, 2003, Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype, Cancer Res, 63, 6643 Wilson, 2010, A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations, J Med Genet, 47, 771, 10.1136/jmg.2010.078113 Beggs, 2010, Peutz-Jeghers syndrome: a systematic review and recommendations for management, Gut, 59, 975, 10.1136/gut.2009.198499 Giardiello, 2000, Very high risk of cancer in familial Peutz-Jeghers syndrome, Gastroenterology, 119, 1447, 10.1053/gast.2000.20228 Tan, 2012, Lifetime cancer risks in individuals with germline PTEN mutations, Clin Cancer Res, 18, 400, 10.1158/1078-0432.CCR-11-2283 Starink, 1986, The Cowden syndrome: a clinical and genetic study in 21 patients, Clin Genet, 29, 222, 10.1111/j.1399-0004.1986.tb00816.x Pilarski, 2013, Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria, J Natl Cancer Inst, 105, 1607, 10.1093/jnci/djt277 Fitzgerald, 2010, Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research, Journal of medical genetics, 47, 436, 10.1136/jmg.2009.074237 Guilford, 2010, Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice, Gastric Cancer, 13, 1, 10.1007/s10120-009-0531-x Hansford, 2015, Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond, JAMA Oncol, 1, 23, 10.1001/jamaoncol.2014.168 Xie, 2011, Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer, Cancer, 117, 3112, 10.1002/cncr.25876 Shah, 2012, De novo CDH1 mutation in a family presenting with early-onset diffuse gastric cancer, Clin Genet, 82, 283, 10.1111/j.1399-0004.2011.01744.x Sugimoto, 2014, Early-onset diffuse gastric cancer associated with a de novo large genomic deletion of CDH1 gene, Gastric Cancer, 17, 745, 10.1007/s10120-013-0278-2 Walsh, 2010, Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry, Clin Cancer Res, 16, 2214, 10.1158/1078-0432.CCR-09-3058 Shulman, 2010, Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome, Obstet Gynecol Clin North Am, 37, 109, 10.1016/j.ogc.2010.03.003 Buerki, 2012, Evidence for breast cancer as an integral part of Lynch syndrome, Genes Chromosomes Cancer, 51, 83, 10.1002/gcc.20935 Win, 2012, Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study, J Clin Oncol, 30, 958, 10.1200/JCO.2011.39.5590 Win, 2013, Risk of breast cancer in Lynch syndrome: a systematic review, Breast Cancer Res, 15, R27, 10.1186/bcr3405 Moldovan, 2009, How the fanconi anemia pathway guards the genome, Annu Rev Genet, 43, 223, 10.1146/annurev-genet-102108-134222 Naslund-Koch, 2016, Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen General Population Study, J Clin Oncol, 34, 1208, 10.1200/JCO.2015.63.3594 Schmidt, 2007, Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation, J Clin Oncol, 25, 64, 10.1200/JCO.2006.06.3024 Guenard, 2010, Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer, Genet Test Mol Biomarkers, 14, 515, 10.1089/gtmb.2010.0027 Weischer, 2012, CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer, J Clin Oncol, 30, 4308, 10.1200/JCO.2012.42.7336 Narod, 2010, Testing for CHEK2 in the cancer genetics clinic: ready for prime time?, Clin Genet, 78, 1, 10.1111/j.1399-0004.2010.01402.x Cybulski, 2011, Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer, J Clin Oncol, 29, 3747, 10.1200/JCO.2010.34.0778 Meijers-Heijboer, 2002, Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations, Nat Genet, 31, 55, 10.1038/ng879 Antoniou, 2014, Breast-cancer risk in families with mutations in PALB2, N Engl J Med, 371, 497, 10.1056/NEJMoa1400382 Catucci, 2012, Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families, Fam Cancer, 11, 483, 10.1007/s10689-012-9540-8 Tischkowitz, 2010, PALB2/FANCN: recombining cancer and Fanconi anemia, Cancer Res, 70, 7353, 10.1158/0008-5472.CAN-10-1012 Renwick, 2006, ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles, Nat Genet, 38, 873, 10.1038/ng1837 Thompson, 2005, Cancer risks and mortality in heterozygous ATM mutation carriers, J Natl Cancer Inst, 97, 813, 10.1093/jnci/dji141 Paglia, 2010, ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy, Breast Cancer Res Treat, 119, 443, 10.1007/s10549-009-0396-z Swift, 1986, The incidence and gene frequency of ataxia-telangiectasia in the United States, Am J Hum Genet, 39, 573 Kurian, 2014, Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment, J Clin Oncol, 32, 2001, 10.1200/JCO.2013.53.6607 Wu, 1996, Identification of a RING protein that can interact in vivo with the BRCA1 gene product, Nat Genet, 14, 430, 10.1038/ng1296-430 Thai, 1998, Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers, Hum Mol Genet, 7, 195, 10.1093/hmg/7.2.195 Ghimenti, 2002, Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations, Genes Chromosomes Cancer, 33, 235, 10.1002/gcc.1223 De Brakeleer, 2010, Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families, Hum Mutat, 31, E1175, 10.1002/humu.21200 Cantor, 2001, BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function, Cell, 105, 149, 10.1016/S0092-8674(01)00304-X Levitus, 2005, The DNA helicase BRIP1 is defective in Fanconi anemia complementation group, J Nat Genet, 37, 934, 10.1038/ng1625 Frank, 2007, BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study, BMC Cancer, 7, 83, 10.1186/1471-2407-7-83 Wong, 2011, BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer, Breast Cancer Res Treat, 127, 853, 10.1007/s10549-011-1443-0 Guenard, 2008, Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families, J Hum Genet, 53, 579, 10.1007/s10038-008-0285-z Seal, 2006, Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles, Nat Genet, 38, 1239, 10.1038/ng1902 Easton, 2016, No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing, J Med Genet, 53, 298, 10.1136/jmedgenet-2015-103529 Lavin, 2007, ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks, Oncogene, 26, 7749, 10.1038/sj.onc.1210880 Damiola, 2014, Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study, Breast Cancer Res, 16, R58, 10.1186/bcr3669 Vaz, 2010, Mutation of the RAD51C gene in a Fanconi anemia-like disorder, Nat Genet, 42, 406, 10.1038/ng.570 Meindl, 2010, Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene, Nat Genet, 42, 410, 10.1038/ng.569 Loveday, 2011, Germline mutations in RAD51D confer susceptibility to ovarian cancer, Nat Genet, 43, 879, 10.1038/ng.893 Baker, 2015, Breast cancer in a RAD51D mutation carrier: case report and review of the literature, Clin Breast Cancer, 15, e71, 10.1016/j.clbc.2014.08.005 Theodoratou, 2010, A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants, Br J Cancer, 103, 1875, 10.1038/sj.bjc.6605966 Nielsen, 2005, Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP), J Med Genet, 42, e54, 10.1136/jmg.2005.033217 Wasielewski, 2010, Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer, Breast Cancer Res Treat, 124, 635, 10.1007/s10549-010-0801-7 Out, 2012, MUTYH gene variants and breast cancer in a Dutch case-control study, Breast Cancer Res Treat, 134, 219, 10.1007/s10549-012-1965-0 Network NCC. Version 2.2016 [Available from: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed [July 22, 2016]. Domchek, 2015, Evolution of genetic testing for inherited susceptibility to breast cancer, J Clin Oncol, 33, 295, 10.1200/JCO.2014.59.3178 Doherty, 2015, Testing for hereditary breast cancer: panel or targeted testing? Experience from a clinical cancer genetics practice, J Genet Couns, 24, 683, 10.1007/s10897-014-9796-2 Domchek, 2008, Genetic variants of uncertain significance: flies in the ointment, J Clin Oncol, 26, 16, 10.1200/JCO.2007.14.4154 Tutt, 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial, Lancet, 376, 235, 10.1016/S0140-6736(10)60892-6 Tutt, 2009, Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer, J Clin Oncol, 27, 10.1200/jco.2009.27.18s.cra501 Gelmon, 2010, Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer, J Clin Oncol, 28 Isakoff, 2010, A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer, J Clin Oncol, 28 Meijers-Heijboer, 2001, Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation, N Engl J Med, 345, 159, 10.1056/NEJM200107193450301 Rebbeck, 2004, Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, J Clin Oncol, 22, 1055, 10.1200/JCO.2004.04.188 Hartmann, 1999, Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer, N Engl J Med, 340, 77, 10.1056/NEJM199901143400201 Hartmann, 2001, Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers, J Natl Cancer Inst, 93, 1633, 10.1093/jnci/93.21.1633 Heemskerk-Gerritsen, 2007, Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic, Ann Surg Oncol, 14, 3335, 10.1245/s10434-007-9449-x Geiger, 2005, A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices, Arch Intern Med, 165, 516, 10.1001/archinte.165.5.516 Domchek, 2010, Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality, JAMA, 304, 967, 10.1001/jama.2010.1237 Ingham, 2013, Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral, Breast Cancer Res Treat, 142, 611, 10.1007/s10549-013-2765-x Guillem, 2006, ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes, J Clin Oncol, 24, 4642, 10.1200/JCO.2005.04.5260 Rebbeck, 2002, Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations, N Engl J Med, 346, 1616, 10.1056/NEJMoa012158 Kauff, 2002, Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation, N Engl J Med, 346, 1609, 10.1056/NEJMoa020119 Rebbeck, 2005, Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, J Clin Oncol, 23, 7804, 10.1200/JCO.2004.00.8151 King, 2001, Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial, JAMA, 286, 2251, 10.1001/jama.286.18.2251 Iodice, 2010, Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis, Eur J Cancer, 46, 2275, 10.1016/j.ejca.2010.04.018 Moorman, 2013, Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis, J Clin Oncol, 31, 4188, 10.1200/JCO.2013.48.9021 Programme NBCS. NHSBSP Publication no., December 2012. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/439601/nhsbsp68.pdf. Accessed [July 22, 2016]. Robson, 2015, American Society of Clinical Oncology Policy Statement update: genetic and genomic testing for cancer susceptibility, J Clin Oncol, 33, 3660, 10.1200/JCO.2015.63.0996 Feero, 2008, J Am Med Inform Assoc, 15, 723, 10.1197/jamia.M2793